Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods – 1 December 2022

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to regulate the manufacturing, supply, and distribution of therapeutic goods, ensuring they meet safety, quality, and efficacy standards. This Act aims to protect public health by controlling the therapeutic goods market, which includes medicines, medical devices, blood, and tissues. The Act empowers the Therapeutic Goods Administration to administer and enforce compliance with the regulatory framework, including the issuance and revocation of manufacturing licences. This legislative measure was enacted to address the need for a robust regulatory system to safeguard consumers against substandard, counterfeit, or unsafe therapeutic goods. In this context, the revocation of a manufacturer's licence, such as the one held by NSW Health Pathology, exemplifies the administration's commitment to maintaining high standards in the therapeutic goods industry. The policy objective remains to ensure that only those entities meeting stringent regulatory criteria are permitted to manufacture therapeutic goods in Australia.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, ensuring they are of acceptable quality, safety, and efficacy. This legislation applies to persons and entities involved in the manufacture, supply, import, and export of therapeutic goods, which include medicines, medical devices, blood, and tissues. The Act encompasses a broad range of industries and conduct, including the quality control and registration of therapeutic goods, with the Therapeutic Goods Administration (TGA) being the regulatory body responsible for enforcement. The geographic reach of the Act is national, applying across the Commonwealth of Australia, including all states and territories. While the Act applies broadly, certain exclusions and exemptions exist, such as for goods that are exempt under the Act or those used for personal, non-commercial purposes. The scope of the Act can also be extended or restricted through subordinate instruments, which provide further detail and specific regulations in line with the overarching legislative framework.

Key Provisions

The key operative sections of this legislation, specifically Section 41(1)(d) of the Therapeutic Goods Act 1989, allow the Secretary to revoke a licence for the manufacture of therapeutic goods at the request of the manufacturer. This section is crucial as it provides a formal process for manufacturers to cease their operations under the licensing scheme. The revocation of the licence held by NSW Health Pathology, with the licence number mi-0808032005-li-000462-1, serves as a clear example of how this section is applied in practice. The notice published on 1 December 2022 by Katherine Clark, the Delegate of the Secretary, confirms the revocation and specifies the details of the licence and the manufacturer involved. The Act imposes several obligations and requirements on the parties it governs. Firstly, it mandates that any manufacturer holding a licence must comply with stringent quality and safety standards as outlined in the Act. If a manufacturer no longer wishes to operate under the licensing scheme, they can request the Secretary to revoke their licence. This process ensures that the manufacturer can formally withdraw from the regulatory framework without any further obligations or liabilities under the Act. The Act also requires the Secretary to publish details of any revocation, ensuring transparency and accountability in the regulatory process. In terms of offences, penalties, or consequences for breach, the Therapeutic Goods Act 1989 does not explicitly detail penalties for the revocation of a licence by request. However, the Act does provide for various penalties related to other breaches of its provisions, such as manufacturing without a licence or producing substandard goods. For example, under Section 31AA of the Act, a person can be subject to a fine of up to $551,000 if they manufacture a therapeutic good without a valid licence. Similarly, under Section 31AB, a person can be fined up to $2.755 million for supplying a therapeutic good that is not of the quality required by the Act. These penalties underscore the importance of compliance with the Act's requirements. The revocation of the licence itself does not carry a specific penalty, but it does result in the cessation of the manufacturer's operations under the Act. This action highlights the importance of adhering to the Act's standards and the consequences of failing to do so. By revoking the licence, the Secretary ensures that the manufacturer no longer has the authority to produce or supply therapeutic goods, thereby protecting public health and safety. The published notice serves as a formal record of the revocation, ensuring that all parties are aware of the manufacturer's changed status under the Act.